| Chronic Obstructive Airway Disease
Breyna vs Yupelri
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Breyna vs Yupelri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYupelri has a higher rate of injection site reactions vs Breyna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yupelri but not Breyna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breyna
Yupelri
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Inhaled (nebulizer)
Once daily
Long-acting muscarinic antagonist
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
Dosing
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease 175 mcg (one unit-dose vial) inhaled once daily via standard jet nebulizer with mouthpiece.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
- Hypersensitivity to revefenacin or any component of this product
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Most common (>=2%) Cough, nasopharyngitis, upper respiratory tract infection, headache, back pain
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Dry mouth
Pharmacology
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Revefenacin is a long-acting muscarinic antagonist (anticholinergic) that competitively and reversibly inhibits M3 receptors at airway smooth muscle, leading to bronchodilation predominantly through a site-specific effect following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
Yupelri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (4/12)
UnitedHealthcare
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Yupelri
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Yupelri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breyna.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreynaView full Breyna profile
YupelriView full Yupelri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.